lancelot vanddispergerbart granulat
dow agrosciences danmark a/s - florasulam, aminopyralid - vanddispergerbart granulat - 150 g/kg florasulam ; 300 g/kg aminopyralid
draxxin
zoetis belgium sa - tulathromycin - antibakterielle midler til systemisk brug - pigs; cattle; sheep - kvæg: behandling og metaphylaxis af bovint respiratorisk sygdom (brd), der er forbundet med mannheimia haemolytica, pasteurella multocida, histophilus somni og mycoplasma bovis følsomme over for tulathromycin. tilstedeværelsen af sygdommen i besætningen bør etableres inden metafylaktisk behandling. behandling af infektiøs bovin keratoconjunctivitis (ibk) forbundet med moraxella bovis følsom overfor tulathromycin. svin: behandling og metaphylaxis af svin respiratorisk sygdom (srd), der er forbundet med actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis og bordetella bronchiseptica følsomme over for tulathromycin. tilstedeværelsen af sygdommen i besætningen bør etableres inden metafylaktisk behandling. draxxin bør kun anvendes, hvis svin forventes at udvikle sygdommen inden for 2-3 dage. får: behandling af de tidlige stadier af infektiøs pododermatitis (fodrot) forbundet med virulent dichelobacter nodosus, der kræver systemisk behandling.
zinplava
merck sharp & dohme b.v. - bezlotoxumab - enterocolitis, pseudomembranøs - immune sera og immunoglobuliner, - zinplava er indiceret til forebyggelse af tilbagefald af clostridium difficile infektion (cdi) hos voksne med høj risiko for gentagelse af cdi.
zeleris
ceva santé animale - florfenicol, meloxicam - amphenicols, kombinationer, antibakterielle midler til systemisk brug - kvæg - for terapeutisk behandling af bovint respiratorisk sygdom (brd), der er forbundet med pyrexia på grund af mannheimia haemolytica, pasteurella multocida og histophilus somni, der er modtagelige for florfenicol.
increxxa
elanco gmbh - tulathromycin - antibakterielle midler til systemisk brug - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. tilstedeværelsen af sygdommen i besætningen bør etableres inden metafylaktisk behandling. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. tilstedeværelsen af sygdommen i besætningen bør etableres inden metafylaktisk behandling. the product should only be used if pigs are expected to develop the disease within 2–3 days. får: behandling af de tidlige stadier af infektiøs pododermatitis (fodrot) forbundet med virulent dichelobacter nodosus, der kræver systemisk behandling.
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. se afsnit 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
raxone
chiesi farmaceutici s.p.a - idebenon - optisk atrofi, arvelig, leber - andre psykostimulantia og nootrope midler, psychoanaleptics, - raxone er indiceret til behandling af synsvanskeligheder hos unge og voksne patienter med leber's hereditary optic neuropathy (lhon).
kefamycin vet. intramammær salve
pharmaxim sweden ab - bacitracin, benzylpenicillinkalium, neomycin - intramammær salve - kvæg
padma 28 tabletter
padma europe gmbh - aegle marmelos frugt, pulver, gul potentil, islandsk mos, kaempferia galanga rhizoma, kryddernellike, morgenfrue blomst, myrobalan frugt, paternostertræ, frugt - tabletter
ultomiris
alexion europe sas - ravulizumab - hemoglobinuri, paroxysmal - selektive immunosuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.